Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Recruiting · NCT06976944 · Registry updated 2026-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-07-13 | NCT06976944 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Yukinori Ozaki | 1 |
14 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Institute Hospital of JFCR | Koto-ku | Japan | 12 |
| Gifu University Hospital | Gifu | Japan | 7 |
| Hiroshima University Hospital | Hiroshima | Japan | 15 |
| Hokkaido University Hospital | Sapporo | Japan | 59 |
| Hyogo Cancer Center | Akashi-shi | Japan | 7 |
| Kindai University Hospital | Sakai-shi | Japan | 6 |
| Nagoya City University Hospital | Nagoya | Japan | 28 |
| Nagoya University Hospital | Nagoya | Japan | 28 |
| National Cancer Center Hospital East | Kashiwa-shi | Japan | 37 |
| National Hospital Organization Nagoya Medical Center | Nagoya | Japan | 8 |
| Okayama University Hospital | Okayama | Japan | 20 |
| Osaka International Cancer Institute | Osaka | Japan | 16 |
| Osaka Metropolitan University Hospital | Osaka | Japan | 3 |
| Showa Medical University Hospital | Shinagawa-ku | Japan | 4 |